Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 3,304 shares, a drop of 33.8% from the December 31st total of 4,991 shares. Based on an average daily trading volume, of 8,064 shares, the short-interest ratio is presently 0.4 days. Currently, 0.2% of the company’s shares are sold short. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 8,064 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Precipio

Several institutional investors and hedge funds have recently added to or reduced their stakes in PRPO. Susquehanna International Group LLP bought a new stake in shares of Precipio during the third quarter worth $194,000. Evernest Financial Advisors LLC acquired a new stake in shares of Precipio during the third quarter valued at about $374,000. Topline Capital Management LLC bought a new stake in shares of Precipio during the third quarter worth about $1,158,000. Finally, AMH Equity Ltd increased its stake in shares of Precipio by 370.1% in the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares during the period. Institutional investors own 10.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Precipio Stock Performance

Shares of Precipio stock traded up $0.28 during trading on Friday, reaching $24.54. The company’s stock had a trading volume of 6,579 shares, compared to its average volume of 9,233. The company has a quick ratio of 1.10, a current ratio of 1.27 and a debt-to-equity ratio of 0.06. The firm has a market cap of $42.95 million, a PE ratio of -29.93 and a beta of 1.12. Precipio has a 52 week low of $3.90 and a 52 week high of $28.50. The business’s 50-day moving average price is $23.99 and its 200-day moving average price is $19.90.

Precipio (NASDAQ:PRPO) last announced its earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. The business had revenue of $6.77 million for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.